BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported better-than-expected second-quarter financial results on Monday. Biomarin Pharmaceutical reported quarterly earnings of 96 cents per share which beat the analyst consensus estimate of 35 cents per share. The company reported quarterly sales of $712.03 million which beat the analyst consensus estimate of $662.05 million, according to data from Benzinga Pro. “Strong execution across our business resulted in record double-digit revenue growth in the second quarter and first half of 2024. These top-line results, along with a focus on operational efficiency, resulted in a 78% year-over-year improvement in quarterly non-GAAP ...